Literature DB >> 20858214

Prodrug design to improve pharmacokinetic and drug delivery properties: challenges to the discovery scientists.

S Jana1, S Mandlekar, P Marathe.   

Abstract

The prodrug design is a versatile, powerful method that can be applied to a wide range of parent drug molecules, administration routes, and formulations. Clinically, the majority of prodrugs are used with the aim of enhancing drug permeation by increasing lipophilicity, or by improving aqueous solubility. Prodrug design may improve the bioavailability of parent molecule, and thus can be integrated into the iterative process of lead optimization, rather than employing it as a post-hoc approach. The purpose of this review is to provide an update of advances and progress in the knowledge of current strategic approaches of prodrug design, along with their real-world utility in drug discovery and development. The review covers the type of prodrugs and functional groups that are amenable to prodrug design. Various prodrug approaches for improving oral drug delivery are discussed, with numerous examples of marketed prodrugs, including improved aqueous solubility, improved lipophilicity, transporter-mediated absorption, and prodrug design to achieve site-specific delivery. Tools employed for prodrug screening, and specific challenges in prodrug research and development are also elaborated. This article is intended to encourage discovery scientists to be creative and consider a rationally designed prodrug approach during the lead optimization phase of drug discovery programs, when the structure activity relationship (SAR) for the drug target is incompatible with pharmacokinetic or biopharmaceutical objectives.

Mesh:

Substances:

Year:  2010        PMID: 20858214     DOI: 10.2174/092986710793205426

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  20 in total

1.  Therapeutic potentials of Crataegus azarolus var. eu- azarolus Maire leaves and its isolated compounds.

Authors:  Eman Abu-Gharbieh; Naglaa Gamil Shehab
Journal:  BMC Complement Altern Med       Date:  2017-04-18       Impact factor: 3.659

2.  Ribonucleoside 3'-phosphates as pro-moieties for an orally administered drug.

Authors:  Michael J Palte; Amy K F Davis; Nicholas A McGrath; Carol A Spiegel; Ronald T Raines
Journal:  ChemMedChem       Date:  2012-07-13       Impact factor: 3.466

3.  Synthesis of a long acting nanoformulated emtricitabine ProTide.

Authors:  Dhruvkumar Soni; Aditya N Bade; Nagsen Gautam; Jonathan Herskovitz; Ibrahim M Ibrahim; Nathan Smith; Melinda S Wojtkiewicz; Bhagya Laxmi Dyavar Shetty; Yazen Alnouti; JoEllyn McMillan; Howard E Gendelman; Benson J Edagwa
Journal:  Biomaterials       Date:  2019-08-20       Impact factor: 12.479

Review 4.  The expanding role of prodrugs in contemporary drug design and development.

Authors:  Jarkko Rautio; Nicholas A Meanwell; Li Di; Michael J Hageman
Journal:  Nat Rev Drug Discov       Date:  2018-04-27       Impact factor: 84.694

5.  Sobetirome prodrug esters with enhanced blood-brain barrier permeability.

Authors:  Andrew T Placzek; Skylar J Ferrara; Meredith D Hartley; Hannah S Sanford-Crane; J Matthew Meinig; Thomas S Scanlan
Journal:  Bioorg Med Chem       Date:  2016-09-16       Impact factor: 3.641

6.  Enhancement of brain-targeting delivery of danshensu in rat through conjugation with pyrazine moiety to form danshensu-pyrazine ester.

Authors:  Ailing Hui; Huayang Yin; Zheng Zhang; An Zhou; Jingchao Chen; Li Yang; Zeyu Wu; Wencheng Zhang
Journal:  Drug Deliv Transl Res       Date:  2018-06       Impact factor: 4.617

7.  Production of recombinant human growth hormone conjugated with a transcytotic peptide in Pichia pastoris for effective oral protein delivery.

Authors:  Jun-Yeong Lee; Sang-Kee Kang; Hui-Shan Li; Chang-Yun Choi; Tae-Eun Park; Jin-Duck Bok; Seung-Ho Lee; Chong-Su Cho; Yun-Jaie Choi
Journal:  Mol Biotechnol       Date:  2015-05       Impact factor: 2.695

Review 8.  Approaches for enhancing oral bioavailability of peptides and proteins.

Authors:  Jwala Renukuntla; Aswani Dutt Vadlapudi; Ashaben Patel; Sai H S Boddu; Ashim K Mitra
Journal:  Int J Pharm       Date:  2013-02-18       Impact factor: 5.875

9.  Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice.

Authors:  Bei Yang; David E Smith
Journal:  Drug Metab Dispos       Date:  2012-12-21       Impact factor: 3.922

Review 10.  The evolution of commercial drug delivery technologies.

Authors:  Ava M Vargason; Aaron C Anselmo; Samir Mitragotri
Journal:  Nat Biomed Eng       Date:  2021-04-01       Impact factor: 25.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.